about
Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationUsing the nonhuman primate model of HCMV to guide vaccine developmentImmune therapy for human papillomaviruses-related cancers.Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.Inhibition of cytomegalovirus infection and photothermolysis of infected cells using bioconjugated gold nanoparticlesValganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trialApproach to drug-resistant cytomegalovirus in transplant recipients.Late emergence of A594V and L595W mutations related to ganciclovir resistance in a patient with HCMV retinitis and long-term HIV progressionEffect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.Human Cytomegalovirus US28 Is Important for Latent Infection of Hematopoietic Progenitor Cells.Human cytomegalovirus pUL97 regulates the viral major immediate early promoter by phosphorylation-mediated disruption of histone deacetylase 1 binding.The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogensCytomegalovirus pneumonia in hematopoietic stem cell recipients.Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus.Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymeraseGanciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.Antiviral drug resistance in herpesviruses other than cytomegalovirus.Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.Mechanism of Anti-rotavirus Synergistic Activity by Epigallocatechin Gallate and a Proanthocyanidin-Containing Nutraceutical.Preparation of the Human Cytomegalovirus Nuclear Egress Complex and Associated Proteins.Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations.Human cytomegalovirus UL97 phosphorylates the viral nuclear egress complexCytomegalovirus antiviral resistance: characterization of results from clinical specimens.Repeated CMV infection in a heart transplantation patient.Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens.Antiviral treatment of cytomegalovirus infection: an update.Ganciclovir-resistant cytomegalovirus infection in transplanted patients: utility of drug monitoring.Impact of RNA polymerase I inhibitor CX-5461 on viral kinase-dependent and -independent cytomegalovirus replication.Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients.
P2860
Q26826856-B5E18724-041C-463A-ABAB-63DE7313A15AQ33584739-08D93DB9-06EE-4954-86F8-83670591D2C5Q34657561-E246391E-8A0A-4105-A5BB-535F8445282DQ34841085-7FF3652F-44C8-4F95-BA07-09E11A198EA5Q34975934-09CBE61C-1F3C-4504-BC74-DA61E319C535Q35200495-2A845A63-6354-4D4F-BFEF-C6A48AA1D7ADQ35735525-3D66DCD1-F5C9-498A-A2EB-B8B0067630C7Q35908691-56A6C309-5D74-4999-BC66-28F354BF8E2BQ36057209-2DB2B2AC-EBE0-4B0D-927F-5B7CE1CD7E8FQ36689547-A112998D-10EE-4042-9167-C7632AC9F8DDQ36736662-75E8BD39-DCC2-4670-B9CE-03FE7D345635Q36978826-1DB95D98-4D77-4E2E-BB4D-75E9AE5AF2EDQ37090265-5BFE8786-ED4A-49EA-9377-21DB7DF4CA0DQ37179131-EF3FA4C2-373F-4006-B76E-3DFAEA885068Q37252826-3930D368-878E-4793-AF06-B35FA697666BQ37523020-F01F01F2-8F0C-4720-A8F7-315BD98F70ABQ37544353-38607182-4035-43B5-BB1B-01AA2171186DQ38194111-72A1CE03-53AE-468F-AAFC-44CC3AD517A5Q38370342-CB0A0052-DB8B-43C7-955C-D8758126D917Q38709692-06B8660E-CE03-4C87-ADE3-CA20FE130730Q38779846-BF7AD216-10EF-430E-AD48-5F6B8FAC640DQ38797660-E4B000BC-1B99-4C41-A01D-75A845AF1D32Q39091219-DBBF3790-D5F6-4988-A3BC-D019DEA0F661Q40217730-EE16DE7B-B04C-48B8-8A4F-92F8CEC8D360Q40829256-55857C29-7E13-4C38-8293-1599C487DA58Q41138845-9D2C1C6D-F70E-4B43-A69B-41B249701E62Q41657330-BBF19EB7-2348-4D44-81C4-286E61FEA7D0Q41691057-D5810AC6-4934-4CF5-92FE-8D763E6760F8Q42214155-FADCB7F1-B2EF-460F-96F2-CDC9ED7DDC4EQ42352189-6FFBF306-9FA1-43C7-9450-869749770095Q43644735-88EE49F2-FA37-4927-8514-1DC340E1DBC9Q43992958-DE38A35C-DD1A-4BC4-A5EC-5C5EED9A8921Q44264370-917D263D-ABC6-49BB-ADDB-847D97E0B267Q49847103-5039698A-C399-415E-A912-130E469169FAQ52640678-6144ED34-E48B-4A22-9798-D0F1609E5CFA
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The biology of cytomegalovirus drug resistance
@ast
The biology of cytomegalovirus drug resistance
@en
type
label
The biology of cytomegalovirus drug resistance
@ast
The biology of cytomegalovirus drug resistance
@en
prefLabel
The biology of cytomegalovirus drug resistance
@ast
The biology of cytomegalovirus drug resistance
@en
P2860
P1476
The biology of cytomegalovirus drug resistance
@en
P2093
Morgan Hakki
Sunwen Chou
P2860
P304
P356
10.1097/QCO.0B013E32834CFB58
P577
2011-12-01T00:00:00Z